株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のHIV診断・治療市場

Diagnostics and Therapeutics for HIV: Global Markets

発行 BCC Research 商品コード 180820
出版日 ページ情報 英文 184 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.13円で換算しております。
Back to Top
世界のHIV診断・治療市場 Diagnostics and Therapeutics for HIV: Global Markets
出版日: 2018年10月24日 ページ情報: 英文 184 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のHIV治療・診断市場は、2018年の220億米ドルから2023年までに271億米ドルへ達すると予測され、この間は4.3%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界のHIV治療・診断市場について調査し、市場概要、産業構造、診断検査の種類、薬剤分類別による治療薬、主要薬剤のプロファイルと薬剤売上の実績、規制、医療費償還と特許などに関する情報を提供しています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 概要

  • HIVの概要
  • HIVのタイムライン・マイルストーン
  • HIVのライフサイクル:治療・作用機序
  • HIVの予防
  • 薬剤耐性

第4章 世界の産業動向

  • 世界のHIV電線
  • 課題

第5章 世界のHIV治療市場

  • 世界のHIV治療市場・予測概要
  • 北米のHIV治療市場
  • 欧州のHIV治療市場
  • その他 (RoW) のHIV治療市場
  • 世界のHIV市場投資

第6章 HIV治療市場:ARV薬剤カテゴリー

  • 治療のタイムライン
  • 市場概要:薬剤カテゴリー別

第7章 HIV治療市場における主な治療薬

  • 主要なHIV治療薬
  • 治療薬プロファイル
  • 有望な新しい治療薬
  • 治療薬の収益予測

第8章 HIV診断市場

  • HIV診断市場:検査タイプ別
  • 抗原・抗体型検査
  • CD4検査
  • ウィルス量検査
  • HIV診断製品プロファイル:検査タイプ別

第9章 パイプライン分析

  • HIVパイプライン概要
  • 開発中のヌクレオシド/核酸系逆転写酵素阻害剤 (NRTI) 治療薬
  • 開発中のNNRTI治療薬
  • その他の分類
  • 併用療法
  • 認可済み・暫定的認可の抗レトロウイルス

第10章 規制・医療費償還構造

  • 規制の概要
  • 価格・医療費償還の概要

第11章 競合情勢・主な発展

  • 市場シェア分析
  • 特許分析
  • 主な発展

第12章 企業プロファイル

  • ABBOTT LABORATORIES
  • ABBVIE INC.
  • AGILENT TECHNOLOGIES INC.
  • AUROBINDO PHARMA LTD.
  • BECTON, DICKINSON AND CO.
  • BIOMERIEUX INC.
  • BIO-RAD LABORATORIES INC.
  • BRISTOL-MYERS SQUIBB CO.
  • CEPHEID INC.
  • CIPLA INC.
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC
  • HOFFMANN-LA ROCHE INC.
  • HOLOGIC INC.
  • JANSSEN PHARMACEUTICALS INC.
  • MERCK & CO. INC.
  • MERIDIAN LIFE SCIENCE INC.
  • MYLAN LABORATORIES
  • SIEMENS HEALTHINEERS
  • THERMO FISHER SCIENTIFIC INC.
  • VIIV HEALTHCARE

第13章 付録:用語

図表

List of Tables

  • Summary Table: Global Market for HIV Therapeutics, by Drug Category, Through 2023
    • Table 1: Milestones in the History of HIV
    • Table 2: Life Cycle of HIV Therapeutics Target Points
    • Table 3: ART Therapy Coverage, by Region, 2017
    • Table 4: Global Market for HIV Therapeutics, by Region, Through 2023
    • Table 5: Global Market for HIV Therapeutics, by Drug Category, Through 2023
    • Table 6: North American Market for HIV Therapeutics, by Drug Category, Through 2023
    • Table 7: European Incidence of HIV, 2014-2016
    • Table 8: European AIDS Diagnosis, by Country, 2014-2016
    • Table 9: European AIDS-related Mortality, by Country, 2014-2016
    • Table 10: HIV Tests Performed in Europe, by Country, 2014-2016
    • Table 11: European ART Therapy Coverage, by Country, 2017
    • Table 12: European Market for HIV Therapeutics, by Drug Category, Through 2023
    • Table 13: Asia-Pacific Incidence and Prevalence of HIV, by Country, 2016 and 2017
    • Table 14: Generic Drug Manufacturers in the Asia-Pacific Region
    • Table 15: Asia-Pacific Market for HIV Therapeutics, by Drug Category, Through 2023
    • Table 16: South America, Middle East and Africa HIV/AIDS Epidemiology, by Region, 2016
    • Table 17: Rest of World Market for HIV Therapeutics, by Drug Category, Through 2023
    • Table 18: Investments on R&D for HIV Cure, by Country, 2012-2016
    • Table 19: Top 20 Private Funders of HIV/AIDS, 2016
    • Table 20: Recommendations of ART Treatment, by WHO, 2016
    • Table 21: Approved NRTIs
    • Table 22: Approved Generic NRTIs
    • Table 23: Global Market for NRTIs, by Region, Through 2023
    • Table 24: Approved PIs
    • Table 25: Approved Generic PIs
    • Table 26: Pharmacokinetic Enhancers, 2017
    • Table 27: Global Market for Protease Inhibitors, by Region, Through 2023
    • Table 28: Approved STRs
    • Table 29: Approved STR FDC Generics
    • Table 30: Global Market for Single-tablet Regimen FDC, by Region, Through 2023
    • Table 31: FDA Approved INSTIs
    • Table 32: Global Market for INSTIs, by Region, Through 2023
    • Table 33: Approved NNRTIs
    • Table 34: Approved Generic NNRTIs
    • Table 35: Global Market for NNRTIs, by Region, Through 2023
    • Table 36: Approved Entry Inhibitors
    • Table 37: Historic Sales of Leading HIV Drugs, 2015-2017
    • Table 38: Historic Sales and Estimated Revenue Forecast of Leading HIV Drugs, Through 2023
    • Table 39: Approved Products, Regulatory Agency
    • Table 40: Global Market for HIV Diagnostics, by Region, Through 2023
    • Table 41: Global Market for HIV Diagnostics, by Test Type, Through 2023
    • Table 42: Antibody HIV Tests
    • Table 43: FDA Approved Antigen-Antibody Combo Tests
    • Table 44: Point-of-care CD4 Tests
    • Table 45: Viral Load Tests, 2013
    • Table 46: Viral Load Tests, 2015
    • Table 47: NRTI Pipeline, 2018
    • Table 48: NRTIs Recently Approved, 2018
    • Table 49: NNRTIs, 2018
    • Table 50: Other Drug Classes in Development, 2018
    • Table 51: Combination Therapies in Development, 2018
    • Table 52: Antiretrovirals Approved and Tentatively Approved by FDA in Association with President's Emergency Plan, 2015-2018
    • Table 53: Preventive Health Services for Children Covered by Private Plans Without Cost Sharing
    • Table 54: Gilead Sciences: Leading Products Revenue, 2015-2017
    • Table 55: GlaxoSmithKline: Leading Products Revenue, 2015-2017
    • Table 56: Johnson & Johnson: Leading Products Revenue, 2015-2017
    • Table 57: Company Market Shares of HIV Therapeutics
    • Table 58: Key U.S. Patents on HIV Diagnostics and Therapeutics
    • Table 59: Key U.S Patents on Blockbuster HIV/AIDS Drugs
    • Table 60: Key Developments in the HIV Market, 2016-2018
    • Table 61: Abbott Laboratories: Marketed Products and Therapeutics
    • Table 62: Abbott Laboratories: Marketed Products and Diagnostics
    • Table 63: Abbott Laboratories: Revenue, 2015-2017
    • Table 64: AbbVie: Net Revenue, 2015-2017
    • Table 65: Agilent Technologies: Marketed Products and Diagnostics
    • Table 66: Agilent Technologies: Revenue, 2015-2017
    • Table 67: Becton, Dickinson and Co.: Marketed Products
    • Table 68: Bio-Rad Laboratories: Marketed Products and Diagnostics
    • Table 69: Bristol-Myers Squibb: Marketed Products
    • Table 70: Bristol-Myers Squibb: Net Revenue, 2015-2017
    • Table 71: Gilead Science: Marketed Products
    • Table 72: Gilead Sciences: Net Revenue, 2015-2017
    • Table 73: GlaxoSmithKline: Net Revenue, 2014-2016
    • Table 74: Hoffmann-La Roche Inc.: Marketed Products, Diagnostics
    • Table 75: Hologic: Marketed Products, Diagnostics
    • Table 76: Janssen Pharmaceuticals: Marketed Products
    • Table 77: Johnson & Johnson: Net Revenue, 2014-2016
    • Table 78: Merck & Co.: Marketed Products
    • Table 79: Merck & Co.: Net Revenue, 2014-2016
    • Table 80: Mylan Laboratories: Marketed Products
    • Table 81: Mylan: Net Revenue, 2015-2017
    • Table 82: Siemens Healthineers: Marketed Products, Diagnostics
    • Table 83: ViiV Healthcare Group of Companies: Marketed Products
    • Table 84: Abbreviations in Diagnostics and Therapeutics for HIV
    • Table 85: Glossary of Terms

List of Figures

  • Summary Figure: Global Market for HIV Therapeutics, by Drug Category, 2017-2023
    • Figure 1: Types of Drug Failure Encountered During HIV Treatment
    • Figure 2: Global Prevalence of HIV, by Region, 2016
    • Figure 3: Global Incidence of HIV, by Region, 2016
    • Figure 4: Global Market for HIV Therapeutics, 2017-2023
    • Figure 5: Global HIV Therapeutics Market Share, by Region, 2017
    • Figure 6: Global HIV Therapeutics Market Share, by Region, 2023
    • Figure 7: Global HIV Therapeutic Market Share, by Drug Category, 2017
    • Figure 8: Global HIV Therapeutics Market Share, by Drug Category, 2023
    • Figure 9: North American Market for HIV Therapeutics, 2017-2023
    • Figure 10: U.S. Historic and Current Incidence of HIV, 2011-2016
    • Figure 11: Canadian Historic and Current Incidence of HIV, 2011-2016
    • Figure 12: North American HIV Therapeutics Market Share, by Drug Category, 2017
    • Figure 13: North American HIV Therapeutics Market Share, by Drug Category, 2023
    • Figure 14: North American Market for HIV Therapeutics, by Country, 2017-2023
    • Figure 15: North American HIV Therapeutics Market Share, by Country, 2017
    • Figure 16: North American HIV Therapeutics Market Share, by Country, 2023
    • Figure 17: European Market for HIV Therapeutics, 2017-2023
    • Figure 18: U.K. Incidence of HIV Among Gay and Bisexual Men, 2015 and 2016
    • Figure 19: European HIV Therapeutics Market Share, by Drug Category, 2017
    • Figure 20: European HIV Therapeutics Market Share, by Drug Category, 2023
    • Figure 21: European Market for HIV Therapeutics, by Country, 2017-2023
    • Figure 22: European HIV Therapeutics Market Share, by Country, 2017
    • Figure 23: European HIV Therapeutics Market Share, by Country, 2023
    • Figure 24: HIV Transmission Share in Australia, by Mode, 2015
    • Figure 25: Asia-Pacific Market for HIV Therapeutics, 2017-2023
    • Figure 26: India's Historic and Current Incidence of HIV, 2005-2016
    • Figure 27: India's Historic and Current Prevalence of HIV, 2005-2016
    • Figure 28: India's Historic and Current AIDS Mortality, 2005-2016
    • Figure 29: South Korea's Historic and Current Incidence of HIV/AIDS Infection, 2001-2016
    • Figure 30: Australia's Historic and Current Incidence of HIV, 2012-2015
    • Figure 31: Singapore's Historic and Current Incidence of HIV/AIDS Infections, 2001-2016
    • Figure 32: Asia-Pacific HIV Therapeutics Market Share, by Drug Category, 2017
    • Figure 33: Asia-Pacific HIV Therapeutics Market Share, by Drug Category, 2023
    • Figure 34: Asia-Pacific Market for HIV Therapeutics, by Country, 2017-2023
    • Figure 35: Asia-Pacific HIV Therapeutics Market Share, by Country, 2017
    • Figure 36: Asia-Pacific HIV Therapeutics Market Share, by Country, 2023
    • Figure 37: Rest of World Market for HIV Therapeutics, 2017-2023
    • Figure 38: Rest of World HIV Therapeutics Market Share, by Drug Category, 2017
    • Figure 39: Rest of World HIV Therapeutics Market Share, by Drug Category, 2023
    • Figure 40: NIH Investments in HIV Research, 2014-2016
    • Figure 41: Private Philanthropic Disbursements for HIV/AIDS, 2007-2016
    • Figure 42: Treatment Switching
    • Figure 43: Global Market for NRTIs, 2017-2023
    • Figure 44: Global Market for NRTIs, by Region, 2017-2023
    • Figure 45: Global Market for Protease Inhibitors, 2017-2023
    • Figure 46: Global Market for Protease Inhibitors, by Region, 2017-2023
    • Figure 47: Global Market for Single-tablet Regimen FDC, 2017-2023
    • Figure 48: Global Market for Single-tablet Regimen FDC, by Region, 2017-2023
    • Figure 49: Global Market for INSTIs, 2017-2023
    • Figure 50: Global Market for INSTIs, by Region, 2017-2023
    • Figure 51: Global Market for NNRTIs, 2017-2023
    • Figure 52: Global Market for NNRTIs, by Region, 2017-2023
    • Figure 53: HIV Diagnostics Test Types, by Category
    • Figure 54: Global Market for HIV Diagnostics, 2017-2023
    • Figure 55: Global Market for HIV Diagnostics, by Region, 2017-2023
    • Figure 56: Global Market for Antigen- and Antibody-based Tests, 2017-2023
    • Figure 57: Global Market for CD4 Tests, 2017-2023
    • Figure 58: Global Market for Viral Load Test, 2017-2023
    • Figure 59: Gilead Sciences: Antiviral Sales, 2015-2017
    • Figure 60: Abbott Laboratories: Revenue Share, by Region, 2017
    • Figure 61: Abbott Laboratories: Revenue Share, by Business Segment, 2017
    • Figure 62: AbbVie: Revenue Share, by Region, 2016
    • Figure 63: Agilent Technologies: Revenue Share, by Region, 2017
    • Figure 64: Agilent Technologies: Revenue Share, by Business Segment, 2017
    • Figure 65: Becton, Dickinson and Co.: Financial Performance, 2013-2017
    • Figure 66: Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2017
    • Figure 67: Becton, Dickinson and Co.: Revenue Share, by Region, 2017
    • Figure 68: Gilead Sciences: Revenue Share, by Region, 2017
    • Figure 69: GlaxoSmithKline: Revenue Share, by Business Segment, 2016
    • Figure 70: GlaxoSmithKline: Revenue Share, by Region, 2016
    • Figure 71: Johnson & Johnson: Revenue Share, by Business Segment, 2017
    • Figure 72: Johnson & Johnson: Revenue Share, by Region, 2017
    • Figure 73: Merck & Co.: Revenue Share, by Business Segment, 2016
    • Figure 74: Merck & Co.: Revenue Share, by Region, 2016
目次
Product Code: PHM058C

Report Highlights:

The global HIV therapeutics market should reach $27.1 billion by 2023 from $22.0 billion in 2018 at a compound annual growth rate (CAGR) of 4.3% for the period of 2018 to 2023.

The single-tablet regimen FDC drug market is expected to grow from $7.9 billion in 2018 to $10.1 billion in 2023 at a CAGR of 4.9% for the period of 2018 to 2023.

The nucleoside/nucleotide reverse transcriptase inhibitors drug market is expected to grow from $6.4 billion in 2018 to $7.9 billion in 2023 at a CAGR of 4.2% for the period of 2018 to 2023.

Report Scope:

This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR during the forecast period. Market data in terms of value is provided at global, regional and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class and discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase stand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

Market dynamics, such as trends and challenges, are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. The regional overviews provide information on the epidemiology of HIV by country and region and details market data for each region. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to readers of this report. The pipeline analysis chapter discusses four major drug categories to provide details on major pipeline developments. The competitive landscape discusses the major manufacturers involved in the HIV therapeutics market, key developments and product offerings.

Report Includes:

  • 37 data tables and 49 additional tables
  • Industry analysis of diagnostics and therapeutics for the HIV disease, and its global markets
  • Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Characterization and quantification of market potential for therapeutic drugs for HIV virus by drug categories, diagnostic test types, application sectors and geographical regions
  • Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
  • Evaluation of the market dynamics such as drivers, restraints and current industry trends and patterns
  • Discussion of the regulatory scenario for United States, Europe, and Japan to provide an overview of the regulations for new drug launches and diagnostic kits
  • Examination of cost implications for treatments across a range of countries
  • A look at ongoing research and the future direction of the market
  • Assessment of the competitive landscape and discussion of the major manufacturers involved in the HIV therapeutics market, key developments and product offerings, including Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview

  • Overview of Human Immunodeficiency Virus (HIV)
    • Report Overview
    • Disease Prognosis
    • Symptoms
    • Treatments
  • HIV Timeline and Milestones
  • HIV Life Cycle: Treatment and Mechanism of Action
  • HIV Prophylaxis
    • Pre-exposure Prophylaxis (PrEP)
    • Post-exposure Prophylaxis (PEP)
  • Drug Resistance
    • Medication Adherence
    • WHO Initiatives

Chapter 4: Global Industry Trends

  • Trends in Global HIV Transmission
    • Regional Awareness Programs
    • Development of Novel Therapies
    • Public-Private Partnerships
    • Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
    • Global Programs to Counter HIV
    • Preventing Transmission from Mother to Child
  • Challenges
    • Underestimating the Risk of Contracting the Disease
    • Social Stigma Associated with STDs
    • High Cost of Treatment

Chapter 5: Global HIV Therapeutics Market

  • Global HIV Therapeutics Market and Forecast Overview
  • North American HIV Therapeutics Market
    • Epidemiology
    • HIV Testing and Recommendations
    • Regulations Impacting the North American HIV Therapeutics Market
    • Market Analysis and Forecast
  • European HIV Therapeutics Market
    • Epidemiology
    • HIV Testing and Recommendations
    • Regulations Impacting the European HIV Market
    • Market Analysis and Forecast
    • Asia-Pacific HIV Therapeutics Market
    • Epidemiology
    • Prevention and Screening Programs
    • Regulations Impacting the Asia-Pacific HIV Market
    • Market Impact of Generic Manufacturers
    • Market Analysis and Forecast
  • Rest of World (RoW) HIV Therapeutics Market
    • Epidemiology
    • Market Analysis and Forecast
  • Global Investments in HIV Market

Chapter 6: HIV Therapeutics Market by ARV Drug Categories

  • Timeline of Therapies
    • First-Line Treatment Regimen
    • Second-line Treatment Regimen
    • Third-line/Salvage Treatment Regimen
  • Market Overview by Drug Category
    • Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
    • Protease Inhibitors (PIs)
    • Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
    • Integrase Strand Transfer Inhibitors (INSTI)
    • Non-nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
    • Entry Inhibitors

Chapter 7: Leading Drugs in the HIV Therapeutics Market

  • Leading HIV Drugs
  • Drug Profiles
    • Genvoya
    • Triumeq
    • Truvada
    • Tivicay (Dolutegravir)
    • Prezista/Prezcobix/Rezolsta/Symtuza
    • Atripla
    • Descovy
    • Isentress/Isentress HD
    • Odefsey
    • Stribild
    • Eviplera
    • Viread
  • Promising Emerging Therapies
    • Darunavir/Cobicistat/FTC/TAF Fixed-dose Combination
    • Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
    • Ibalizumab (Trogarzo)
  • Estimated Drug Revenue Forecast
    • Genvoya
    • Triumeq and Tivicay
    • Odefsey
    • Stribild

Chapter 8: HIV Diagnostics Market

  • HIV Diagnostics Market by Test Type
    • Evolution of HIV Tests
  • Antigen- and Antibody-Based Tests
    • Future Perspective
  • CD4 Testing
    • Future Perspective
  • Viral Load Testing
    • Future Perspective
  • HIV Diagnostics Product Profiles by Test Type
    • CD4 Testing Products
    • Viral Load Testing Products

Chapter 9: Pipeline Analysis

  • HIV Pipeline Overview
  • Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Drugs in Development
  • NNRTI Drugs in Development
    • Doravirine/TDF/3TC
  • Other Categories
    • Generic Dolutegravir (Integrase Inhibitors)
    • Albuvirtide (Aikening) (Fusion inhibitors)
    • Juluca (Dolutegravir/Rilpivirine)
    • Isentress HD (Raltegravir) (Integrase Inhibitors)
  • Combination Therapies
  • Approved and Tentatively Approved Antiretrovirals

Chapter 10: Regulatory and Reimbursement Structure

  • Overview of Regulations
    • United States
    • Europe
    • Japan
    • China
  • Overview of Pricing and Reimbursement
    • United States
    • Europe
    • Japan

Chapter 11: Competitive Landscape and Key Developments

  • Market Share Analysis
  • Patent Analysis
  • Key Developments

Chapter 12: Company Profiles

  • ABBOTT LABORATORIES
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • ABBVIE INC.
    • Company Overview
    • Financials
  • AGILENT TECHNOLOGIES INC.
    • Company Overview
    • Product Information
    • Financials
  • AUROBINDO PHARMA LTD.
    • Company Overview
  • BECTON, DICKINSON AND CO.
    • Company Overview
    • Product Information
    • Key Developments and Strategies
    • Financials
  • BIOMERIEUX INC.
    • Company Overview
  • BIO-RAD LABORATORIES INC.
    • Company Overview
    • Product Overview
  • BRISTOL-MYERS SQUIBB CO.
    • Company Overview
    • Product Information
    • Financials
  • CEPHEID INC.
    • Company Overview
  • CIPLA INC.
    • Company Overview
  • GILEAD SCIENCES INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • GLAXOSMITHKLINE PLC
    • Company Overview
    • Development and Strategies
    • Financials
  • HOFFMANN-LA ROCHE INC.
    • Company Overview
    • Product Information
  • HOLOGIC INC.
    • Company Overview
    • Product Overview
  • JANSSEN PHARMACEUTICALS INC.
    • Company Overview
    • Product Information
    • Developments and Strategies
    • Financials
  • MERCK & CO. INC.
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • MERIDIAN LIFE SCIENCE INC.
    • Company Overview
  • MYLAN LABORATORIES
    • Company Overview
    • Product Information
    • Development and Strategies
    • Financials
  • SIEMENS HEALTHINEERS
    • Company Overview
    • Product Overview
  • THERMO FISHER SCIENTIFIC INC.
    • Company Overview
  • VIIV HEALTHCARE
    • Company Overview
    • Product Information

Chapter 13: Appendix: Abbreviations and Glossary

  • Abbreviations
  • Glossary of Terms
Back to Top